Aslıhan DOĞRU -TDO- American biotechnology company Moderna has applied for the use of the new type of coronavirus (Covid-19) vaccine in young people in the European Union (EU) and Canada.
At the beginning of the summer, initiatives were launched in EU countries and Canada for the use of the Covid-19 vaccine in children between the ages of 12 and 18, the company said in a statement.
The company also announced plans to apply for emergency approval with the Food and Drug Administration (FDA) in the United States, where the Pfizer-BioNTech vaccine is already administered to adolescents 12 years and older.
"We are pleased to submit our Covid-19 vaccine for use in adolescents in the EU to the Conditional Marketing Approval of the European Medicines Agency. We've applied for authorization in Canada. We are encouraged that our vaccine is highly effective in preventing Covid-19 and SARS-CoV-2 infection in adolescents," Moderna Executive Director Stephane Bancel said.